Signaling inhibitors in the treatment of prostate cancer (Q34722254)

4 August 2017

1 reference

title

Signaling inhibitors in the treatment of prostate cancer (English)

1 reference

4 August 2017

1 reference

Gary R Hudes

1

1 reference

4 August 2017

language of work or name

1 reference

1 May 2002

1 reference

Investigational New Drugs

4 August 2017

published in

1 reference

4 August 2017

volume

20

1 reference

4 August 2017

issue

2

1 reference

4 August 2017

page(s)

159-172

1 reference

Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase

4 August 2017

cites work

1 reference

12 December 2020

Androgen-independent induction of prostate-specific antigen gene expression via cross-talk between the androgen receptor and protein kinase A signal transduction pathways

1 reference

12 December 2020

12(S)-HETE enhancement of prostate tumor cell invasion: selective role of PKC alpha

1 reference

12 December 2020

Requirement of Ras-GTP-Raf Complexes for Activation of Raf-1 by Protein Kinase C

1 reference

12 December 2020

Insulin-like growth factors and prostate cancer

1 reference

12 December 2020

A Phase II trial of bryostatin-1 for patients with metastatic renal cell carcinoma

1 reference

12 December 2020

Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor alpha in the progression of prostatic neoplasms

1 reference

12 December 2020

The in vivo effect of bryostatin-1 on paclitaxel-induced tumor growth, mitotic entry, and blood flow

1 reference

12 December 2020

Her-2-neu expression and progression toward androgen independence in human prostate cancer.

1 reference

12 December 2020

Androgen receptor--an update of mechanisms of action in prostate cancer

1 reference

12 December 2020

Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor

1 reference

12 December 2020

Structural assets of a tumor suppressor.

1 reference

12 December 2020

Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy

1 reference

12 December 2020

Phase I study of bryostatin 1: assessment of interleukin 6 and tumor necrosis factor alpha induction in vivo. The Cancer Research Campaign Phase I Committee

1 reference

12 December 2020

A phase II trial of bryostatin 1 in the treatment of metastatic colorectal cancer.

1 reference

12 December 2020

Interleukin-6 induces prostate cancer cell growth accompanied by activation of stat3 signaling pathway .

1 reference

12 December 2020

1 reference

12 December 2020

Expression of androgen receptor coregulatory proteins in prostate cancer and stromal-cell culture models

1 reference

12 December 2020

Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor

1 reference

12 December 2020

Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN.

1 reference

12 December 2020

A phase II study of bryostatin 1 in metastatic malignant melanoma

1 reference

12 December 2020

Role of diacylglycerol-regulated protein kinase C isotypes in growth factor activation of the Raf-1 protein kinase

1 reference

12 December 2020

Cell kinetic measurements in prostate cancer

1 reference

12 December 2020

A multi-institutional phase ii study of SU101, a platelet-derived growth factor receptor inhibitor, for patients with hormone-refractory prostate cancer

1 reference

12 December 2020

Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy.

1 reference

12 December 2020

Epidermal growth factor (EGF) receptor blockade inhibits the action of EGF, insulin-like growth factor I, and a protein kinase A activator on the mitogen-activated protein kinase pathway in prostate cancer cell lines

1 reference

12 December 2020

Phase II trial of bryostatin 1 in patients with relapsed low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia

1 reference

12 December 2020

Successful treatment of murine melanoma with bryostatin 1.

1 reference

12 December 2020

Dephosphorylation of activated protein kinase C contributes to downregulation by bryostatin

1 reference

12 December 2020

Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice

1 reference

12 December 2020

Non-Ras targets of farnesyltransferase inhibitors: focus on Rho.

1 reference

12 December 2020

Direct demonstration of geranylgeranylation and farnesylation of Ki-Ras in vivo

1 reference

12 December 2020

Natural history of progression after PSA elevation following radical prostatectomy

1 reference

12 December 2020

Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics

1 reference

12 December 2020

Protein kinase C isoenzyme patterns characteristically modulated in early prostate cancer

1 reference

12 December 2020

Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras?

1 reference

12 December 2020

Mutational Status of Codons 12 and 13 of the N- andK-rasGenes in Tissue and Cell Lines Derived from Primary and Metastatic Prostate Carcinomas

1 reference

12 December 2020

Treatment with farnesyl-protein transferase inhibitor induces regression of mammary tumors in transforming growth factor (TGF) alpha and TGF alpha/neu transgenic mice by inhibition of mitogenic activity and induction of apoptosis

1 reference

12 December 2020

Signal transduction by the neurotrophin receptors

1 reference

12 December 2020

Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells

1 reference

12 December 2020

Response of prostate cancer cells to peptide growth factors: transforming growth factor-beta

1 reference

12 December 2020

Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays.

1 reference

12 December 2020

From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells

1 reference

12 December 2020

Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression

1 reference

12 December 2020

Infrequent RAS oncogene mutations in human prostate cancer

1 reference

12 December 2020

Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression

1 reference

12 December 2020

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

12 December 2020

A signaling pathway to translational control

1 reference

12 December 2020

Cell cycle-independent death of prostate adenocarcinoma is induced by the trk tyrosine kinase inhibitor CEP-751 (KT6587)

1 reference

12 December 2020

Rapid signalling by androgen receptor in prostate cancer cells

1 reference

12 December 2020

Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity

1 reference

12 December 2020

Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor

1 reference

12 December 2020

Activated ras alleles in human carcinoma of the prostate are rare.

1 reference

12 December 2020

Signaling inhibitors in the clinic: new agents and new challenges

1 reference

12 December 2020

Characterization of Ha-ras, N-ras, Ki-Ras4A, and Ki-Ras4B as in vitro substrates for farnesyl protein transferase and geranylgeranyl protein transferase type I

1 reference

12 December 2020

New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway

1 reference

12 December 2020

A phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusion.

1 reference

12 December 2020

A phase I study of intravenous bryostatin 1 in patients with advanced cancer

1 reference

12 December 2020

Fluorescence in situ hybridization study of HER-2/neu oncogene amplification in prostate cancer

1 reference

12 December 2020

ras oncogenes in human cancer: a review

1 reference

12 December 2020

Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones

1 reference

12 December 2020

Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage.

1 reference

12 December 2020

Inhibition of platelet-derived growth factor-mediated signal transduction and tumor growth by N-[4-(trifluoromethyl)-phenyl]5-methylisoxazole-4-carboxamide

1 reference

12 December 2020

Androgen and epidermal growth factor down-regulate cyclin-dependent kinase inhibitor p27Kip1 and costimulate proliferation of MDA PCa 2a and MDA PCa 2b prostate cancer cells

1 reference

12 December 2020

PDGF-D is a specific, protease-activated ligand for the PDGF beta-receptor

1 reference

12 December 2020

PDGF-D, a new protease-activated growth factor

1 reference

12 December 2020

Frequent inactivation of PTEN in prostate cancer cell lines and xenografts

1 reference

12 December 2020

Correlation of p34cdc2 cyclin-dependent kinase overexpression, CD44s downregulation, and HER-2/neu oncogene amplification with recurrence in prostatic adenocarcinomas

1 reference

12 December 2020

Immunohistochemistry analysis of platelet-derived growth factor A and B chains and platelet-derived growth factor alpha and beta receptor expression in benign prostatic hyperplasias and Gleason-graded human prostate adenocarcinomas

1 reference

12 December 2020

Preclinical pharmacology of the natural product anticancer agent bryostatin 1, an activator of protein kinase C.

1 reference

12 December 2020

Dual Role of Phosphatidylinositol-3,4,5-trisphosphate in the Activation of Protein Kinase B

1 reference

12 December 2020

Signaling Through Scaffold, Anchoring, and Adaptor Proteins

1 reference

12 December 2020

Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555)

1 reference

12 December 2020

Protein prenylation: key to ras function and cancer intervention?

1 reference

12 December 2020

Peptide growth factors and prostate cancer: new models, new opportunities

1 reference

12 December 2020

Focal adhesion kinase, Rap1, and transcriptional induction of vascular endothelial growth factor

1 reference

12 December 2020

A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase.

1 reference

12 December 2020

Beta-catenin affects androgen receptor transcriptional activity and ligand specificity

1 reference

12 December 2020

Mechanism of action and in vivo role of platelet-derived growth factor

1 reference

12 December 2020

Effects of activators of protein kinase C, including bryostatins 1 and 2, on the growth of A549 human lung carcinoma cells

1 reference

12 December 2020

The mRNA 5' cap-binding protein eIF4E and control of cell growth

1 reference

12 December 2020

Dysregulated expression of growth factors and their receptors in the development of prostate cancer

1 reference

12 December 2020

Mechanisms and consequences of activation of protein kinase B/Akt

1 reference

12 December 2020

Modulation of drug-induced apoptosis by interruption of the protein kinase C signal transduction pathway: a new therapeutic strategy

1 reference

12 December 2020

Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C

1 reference

12 December 2020

Tyrosine kinases expressed in vivo by human prostate cancer bone marrow metastases and loss of the type 1 insulin-like growth factor receptor

1 reference

12 December 2020

Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor

1 reference

12 December 2020

K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors

1 reference

12 December 2020

Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors

1 reference

12 December 2020

Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer

1 reference

12 December 2020

Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 in patients with advanced solid tumors

1 reference

12 December 2020

Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development

1 reference

12 December 2020

Rational basis for Trk inhibition therapy for prostate cancer.

1 reference

12 December 2020

Ligand-induced conformational alterations of the androgen receptor analyzed by limited trypsinization. Studies on the mechanism of antiandrogen action

1 reference

12 December 2020

Nerve growth factor: a tale of two receptors

1 reference

12 December 2020

Differential effects of bryostatin 1 and phorbol ester on human breast cancer cell lines.

1 reference

12 December 2020

Activation of the human androgen receptor through a protein kinase A signaling pathway

1 reference

12 December 2020

4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt(PKB) signaling pathway

1 reference

12 December 2020

Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor

1 reference

12 December 2020

Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C.

1 reference

12 December 2020

Implication of cell kinetic changes during the progression of human prostatic cancer

1 reference

12 December 2020

Cancer statistics, 2001

1 reference

12 December 2020

Identifiers

DOI

10.1023/A:1015678427111

1 reference

Dimensions Publication ID

4 August 2017

1019808465

0 references

1 reference